Learn more about whether Charles River Laboratories International, Inc. or Illumina, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics ...

Illumina (NASDAQ:ILMN) supports global genomic science as nasdaq futures discussions include advanced life sciences platforms ...

Vossman discusses the genomics landscape, as well as next-generation sequencing (or NGS), and the Model Project, a ...

Why Illumina’s Latest Move Has Investors Watching Closely Illumina (ILMN) just deepened its bet on clinical whole genome sequencing by investing in and partnering with MyOme, backing a large Proactive ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

According to MarketsandMarkets™, The report Single-molecule Real-time (SMRT) Sequencing Market is projected to grow from USD ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Altman was asked about OpenAI’s $1.4trn commitment to players in the AI value chain. His answer is a good encapsulation of ...

Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia ...

Pacific Biosciences of California, Inc. is downgraded to Hold with slow commercial adoption & academic funding pressures.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...